May 13th 2024
Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Roundtable Discussion: Udhrain Discusses Treatment Management in Patients With Extensive-Stage SCLC
October 15th 2021In a 73-year-old patient, a PET scan revealed activity in the left upper lobe mass, supraclavicular nodal areas, and liver lesions, and an MRI discovered 1 small asymptomatic brain lesion. This lead to a diagnosis of stage T3N3M1-IV extensive-stage small cell lung cancer.
Read More
Race Does Not Correlate With High Renal Toxicity With Pemetrexed/Pembrolizumab in NS-NSCLC
October 11th 2021In an interview with Targeted Oncology, Nino Balanchivadze, MD, FACP, discussed the toxicity profile of platinum pemetrexed with pembrolizumab in patients with nonsquamous NSCLC treated in the KEYNOTE-189 study and how demographics and clinical characteristics may impact treatment.
Read More
Roundtable Discussion: Participants Explore Molecular Testing in the Lung Cancer Setting
October 8th 2021A 59-year-old man presented with dyspnea on exertion, fatigue, anorexia, and a 5-lb weight loss. He received the diagnosis of stage IVA adenocarcinoma and had an ECOG performance status of 1.
Read More
In Unresectable Stage III NSCLC, Real-World PFS Benefit Reported With PACIFIC Regimen
September 21st 2021Compared with the median PFS reported in the durvalumab arm of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer, the median real-world progression-free survival with durvalumab was higher.
Read More